BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Legacy Advisors, LLC 1,020$354,0000.07%
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO 38,214$13,247,0000.07%
Qube Research & Technologies Ltd 27,912$9,675,0000.07%
Granite Investment Partners, LLC 4,849$1,681,0000.07%
ClearBridge Investments 212,660$73,716,0000.07%
NEW YORK STATE COMMON RETIREMENT FUND 150,281$52,093,0000.07%
BTC Capital Management, Inc. 1,576$549,0000.07%
Sumitomo Mitsui Trust Holdings, Inc. 247,279$85,717,0000.07%
Ethic Inc. 2,543$882,0000.06%
JANUS HENDERSON GROUP PLC 249,311$86,422,0000.06%
NATIXIS ADVISORS, L.P. 39,528$13,702,0000.06%
Rossmore Private Capital 1,000$347,0000.06%
Renaissance Technologies 146,200$50,679,0000.06%
Parkside Financial Bank & Trust 568$197,0000.06%
Ameritas Investment Partners, Inc. 3,930$1,361,0000.06%
Advisors Asset Management, Inc. 8,695$3,014,0000.06%
Point72 Hong Kong Ltd 4,481$1,553,0000.06%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 474,852$164,603,0000.06%
SHELL ASSET MANAGEMENT CO 5,516$1,912,0000.06%
PARSONS CAPITAL MANAGEMENT INC/RI 1,785$619,0000.06%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.